Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship products include FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration; and FerriSmart, an automated software medical device to manage patients with iron overload disorders, such as thalassemia, sickle cell disease, hereditary haemochromatosis, anaemias, and cancers. The company also offers Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; HepaFat-AI, an artificial intelligence software tool, which is used for the automated assessment of liver fat from MRI data; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials. The company serves clinicians for the diagnosis and management of human diseases; researchers; and pharmaceutical companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
Read More
